OLIMMUNE
Olimmune is a developer of groundbreaking oligonucleotide immunotherapies for treatment-resistant and metastatic cancers. Olimmune’s lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers.
OLIMMUNE
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Pasadena, California, United States
Country:
United States
Website Url:
http://www.olimmune.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Holobeam Technologies
Holobeam Technologies is developing a new technology for treating cancer and other diseases using holography.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
TeraImmune
TeraImmune is a developer of cell therapeutics created for autoimmune diseases and immune-related disorders.
Current Employees Featured
More informations about "Olimmune"
Olimmune Company Profile 2024: Valuation, Investors ... - PitchBook
Olimmune General Information Description. Developer of oligonucleotide immunotherapies intended to treat resistant and metastatic cancers. The company offers therapeutic drug for …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with
Jun 30, 2021 Olimmune’s lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitted …See details»
Scopus BioPharma Announces New Management Appointment …
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune (06.30.21) FINAL. Home; Investors. Company Information; Press Releases; SEC Filings; Stock Data; …See details»
Olimmune, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Explore Olimmune, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Olimmune - Ownership and Business Overview - Mergr
Jun 30, 2021 Olimmune was founded in 2019 and is based in Los Angeles, California. Company Summary. SECTOR. Life Science. Established. 2019. Investor History; 2021-06-30 Add-on …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
Olimmune’s lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitted by Q1 2023.See details»
Olimmune - Products, Competitors, Financials, Employees, …
Olimmune is an immunotherapy company engineering bispecific oligonucleotides for the treatment of solid tumors. On June 30, 2021, Olimmune was acquired by Scopus BioPharma. Use the …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
Jun 30, 2021 Olimmune’s lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitted …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
Title: Microsoft Word - Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune (06.30.21) FINAL.docx Author: Robert J. GibsonSee details»
Scopus BioPharma Announces New Management Appointment …
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious …See details»
Scopus BioPharma Announces New Management Appointment
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing...See details»
Scopus BioPharma Expands Immunotherapy Pipeline with
--Scopus BioPharma Inc., a clinical-stage biopharmaceutical company developing transformational therapeutics, today announced the acquisition of Los Angeles- based …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
On June 30, 2021, (GLOBE NEWSWIRE) reported, Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics, today …See details»
Olimmune, Inc. | Insights
Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Scopus BioPharma Launches Duet Therapeutics - GlobeNewswire
Sep 2, 2021 Duet Therapeutics integrates the management and clinical development of the immunotherapy assets of Scopus and Olimmune, acquired by Scopus in June 2021. Duet is a …See details»
Scopus BioPharma Inc. acquired Olimmune Inc. - MarketScreener
Jun 29, 2021 Scopus BioPharma Inc. (NasdaqGM:SCPS) entered into an agreement to acquire Olimmune Inc. for $14.3 million on June 25, 2021. The consideration paid Scopus issued to …See details»
Scopus Biopharma Flexes Immuno-Oncology Pipeline Following Its ...
Sep 3, 2021 Scopus Biopharma, a New York-based clinical-stage biopharmaceutical firm, recently launched Duet Therapeutics to integrate its immunotherapy assets’ management and …See details»
Scopus BioPharma's Subsidiary — Duet Therapeutics — to
Sep 22, 2021 Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet …See details»
Scopus BioPharma Expands Immunotherapy Pipeline with …
Jun 30, 2021 Detailed price information for Scopus Biopharma Inc (SCPS) from The Globe and Mail including charting and trades.See details»